The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), is back in the green in 2025 as of the Apr. 21 close. Shares were down moderately in 2025 through mid-April. However, huge news came out regarding one of the company’s experimental drugs, causing shares to spike by over 14%.
That drug is orforglipron, Eli Lilly’s GLP-1 drug that patients administer orally rather than through an injectable pen. The results of orforglipron’s Phase 3 Food and Drug Administration (FDA) trial greatly impressed investors.
